On September 10, 2025, Purgo Biologics signed an MOU with KAID at its Pangyo headquarters. Through this partnership, Purgo expects to further expand the use and promotion of implant-related grafting materials and contribute to academic advancement. From KAID’s perspective, Purgo, as the only domestic xenograft manufacturer, has obtained approval in 56 countries worldwide and exports to 47 countries, with a strong portfolio of SCI-indexed publications, thereby making significant contributions to the academic development of the association. Following the signing ceremony, both parties shared their visions and goals over a casual meal.